Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2009844 | 0.80 | KEAP1 (0.38) | CYP2C9CYP2C19LMNAMEN1KMT2A | |
| SCHEMBL2013425 | 0.79 | MEN1 (0.55) | LMNASMN1; SMN2MEN1KMT2APTGES2 | |
| SCHEMBL18297695 | 0.75 | PSIP1 (0.43) | PSIP1CYP3A4CYP2C9CYP2C19ERN1 | |
| SCHEMBL17048148 | 0.75 | TDP1 (0.38) | PSIP1CYP3A4LMNASMN1; SMN2MEN1 | |
| SCHEMBL632301 | 0.74 | L3MBTL1 (0.49) | PSIP1CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL5559272 | 0.74 | ALDH1A1 (0.46) | CYP3A4CYP2C9CYP2C19ERN1LMNA | |
| SCHEMBL95708 | 0.73 | ERN1 (0.50) | ERN1LMNAKCNH2MEN1KMT2A | |
| SCHEMBL14017790 | 0.73 | GAA (0.45) | LMNASMN1; SMN2MEN1KMT2ATRPA1 | |
| SCHEMBL29469859 | 0.72 | PTGES2 (0.49) | PTGES2 | |
| SCHEMBL3634673 | 0.72 | HDAC1 (0.42) | LMNASMN1; SMN2MEN1KMT2ATRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964727-B2 | N-({1-[(cis-1,4-dihydroxycyclohexyl)methyl]piperidin-4-yl}methyl)-1-isopropyl-5-methyl-2-oxo-1, 2-dihydroquinoline-3-carboxamide ethanedioate; gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome | PFIZER INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964727-B2 | N-({1-[(cis-1,4-dihydroxycyclohexyl)methyl]piperidin-4-yl}methyl)-1-isopropyl-5-methyl-2-oxo-1, 2-dihydroquinoline-3-carboxamide ethanedioate; gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome | PFIZER INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964727-B2 | N-({1-[(cis-1,4-dihydroxycyclohexyl)methyl]piperidin-4-yl}methyl)-1-isopropyl-5-methyl-2-oxo-1, 2-dihydroquinoline-3-carboxamide ethanedioate; gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome | PFIZER INC. (US) | 2011-06-21 | — | — | US | disclosed |
| EP-1689742-B1 | QUINOLONECARBOXYLIC ACID COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER (US) | 2010-03-17 | — | — | EP | disclosed |
| EP-1689742-B1 | QUINOLONECARBOXYLIC ACID COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20080255113-A1 | Quinolonecarboxylic Acid Compounds Having 5-Ht4 Receptor Agonistic Activity | KATO TOMOKI | 2008-10-16 | — | — | US | disclosed |
| US-20080255113-A1 | Quinolonecarboxylic Acid Compounds Having 5-Ht4 Receptor Agonistic Activity | KATO TOMOKI | 2008-10-16 | — | — | US | disclosed |
| US-20080255113-A1 | Quinolonecarboxylic Acid Compounds Having 5-Ht4 Receptor Agonistic Activity | KATO TOMOKI | 2008-10-16 | — | — | US | disclosed |
| EP-1689742-A1 | QUINOLONECARBOXYLIC ACID COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | Pfizer, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005049608-A1 | QUINOLONECARBOXYLIC ACID COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER JAPAN, INC. (JP) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049608-A1 | QUINOLONECARBOXYLIC ACID COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER JAPAN, INC. (JP) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255113-A1 | Quinolonecarboxylic Acid Compounds Having 5-Ht4 Receptor Agonistic Activity | HTR4, HRH4, HRH2 | PSIP1 2345/4885CYP3A4 126/4885CYP2C9 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.